Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pozen, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Pozen, Inc. - Product Pipeline Review - 2015', provides an overview of the Pozen, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Pozen, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Pozen, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Pozen, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Pozen, Inc.'s pipeline products Reason to Buy - Evaluate Pozen, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Pozen, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Pozen, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Pozen, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pozen, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Pozen, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Pozen, Inc. Snapshot 5 Pozen, Inc. Overview 5 Key Information 5 Key Facts 5 Pozen, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Pozen, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Pozen, Inc. - Pipeline Products Glance 11 Pozen, Inc. - Late Stage Pipeline Products 11 Filing rejected/Withdrawn Products/Combination Treatment Modalities 11 Phase III Products/Combination Treatment Modalities 12 Pozen, Inc. - Clinical Stage Pipeline Products 13 Phase I Products/Combination Treatment Modalities 13 Pozen, Inc. - Drug Profiles 14 PA-32540 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 PA-8140 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 (sumatriptan succinate + naproxen sodium) 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PA-10040 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PA-65020 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Pozen, Inc. - Pipeline Analysis 21 Pozen, Inc. - Pipeline Products by Target 21 Pozen, Inc. - Pipeline Products by Route of Administration 22 Pozen, Inc. - Pipeline Products by Molecule Type 23 Pozen, Inc. - Pipeline Products by Mechanism of Action 24 Pozen, Inc. - Recent Pipeline Updates 25 Pozen, Inc. - Dormant Projects 30 Pozen, Inc. - Company Statement 31 Pozen, Inc. - Locations And Subsidiaries 33 Head Office 33 Other Locations & Subsidiaries 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List of Tables
Pozen, Inc., Key Information 5 Pozen, Inc., Key Facts 5 Pozen, Inc. - Pipeline by Indication, 2015 7 Pozen, Inc. - Pipeline by Stage of Development, 2015 8 Pozen, Inc. - Monotherapy Products in Pipeline, 2015 9 Pozen, Inc. - Combination Treatment Modalities in Pipeline, 2015 10 Pozen, Inc. - Filing rejected/Withdrawn, 2015 11 Pozen, Inc. - Phase III, 2015 12 Pozen, Inc. - Phase I, 2015 13 Pozen, Inc. - Pipeline by Target, 2015 21 Pozen, Inc. - Pipeline by Route of Administration, 2015 22 Pozen, Inc. - Pipeline by Molecule Type, 2015 23 Pozen, Inc. - Pipeline Products by Mechanism of Action, 2015 24 Pozen, Inc. - Recent Pipeline Updates, 2015 25 Pozen, Inc. - Dormant Developmental Projects,2015 30 Pozen, Inc., Subsidiaries 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.